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Mass Oral Azithromycin for Childhood 
Mortality: Timing of Death After 
Distribution in the MORDOR Trial
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8Blantyre Institute for Community Outreach, and 9College of Medicine, University of Malawi, 
Blantyre; and 10National Institute for Medical Research, Dar es Salaam, Tanzania
In a large community-randomized trial, biannual azithromy-
cin distributions significantly reduced postneonatal child-
hood mortality in sub-Saharan African sites. Here, we present 
a prespecified secondary analysis showing that much of the 
protective effect was in the first 3  months postdistribution. 
Distributing more frequently than biannually could be consid-
ered if logistically feasible.
Clinical Trials Registration. NCT02047981.
Keywords. childhood mortality; azithromycin; sub-Saharan 
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Trachoma programs have distributed >700 million doses of sin-
gle-dose oral azithromycin to eliminate the strains of chlamydia 
that cause the blinding disease [1]. Azithromycin may also have 
collateral benefits against a number of infectious diseases includ-
ing malaria, diarrhea, and pneumonia [2–7]. Several studies have 
suggested that mass azithromycin may reduce childhood mortal-
ity [8, 9]. The MORDOR trial (Macrolides Oraux pour Réduire 
les Décès avec un Oeil sur la Résistance) found that azithromycin 
distributions significantly reduced postneonatal childhood mor-
tality by 14% across sites in Malawi, Niger, and Tanzania [10].
The timing and frequency of distributions in MORDOR 
were determined by logistical reasons. Secondary analysis of 
MORDOR could reveal the duration of azithromycin’s pro-
tective effect and suggest a preferential season for distributions. 
Here, we compared the survival time posttreatment in the 
azithromycin- and placebo-treated communities. In those chil-
dren who died, we compared the distribution of time of death 
posttreatment in the 2 arms, and separately the season of treat-
ment and the season of death.
METHODS
MORDOR was a community-randomized trial conducted in 
the Malawian district of Mangochi, the Nigerien districts of 
Boboye and Loga, and the Tanzanian district of Kilosa [10]. The 
1533 randomization units were the health surveillance assistant 
area in Malawi, the grappe in Niger, and the hamlet in Tanzania. 
Communities with a population between 200 and 2000 inhab-
itants on the most recent census were eligible for enrollment. 
Enrollment was based on census information available prior 
to the study. Communities remained in the study even if the 
population size drifted out of this numerical range. Children 
aged 1–59  months who weighed at least 3800  g were eligible 
for azithromycin or placebo. Biannual distributions were per-
formed over each district in a rolling fashion, over a 6-month 
prespecified time period (8 months for the initial census and 
distribution) [10]. Thus, treatments could be given any time 
during the year. The estimated time of death was collected dur-
ing the subsequent census.
Statistical Analysis
We compared survival between the treatment and control 
groups using the log-rank test. Unfortunately, this survival 
analysis, in essence, reiterates the main finding of a mortality 
difference between the 2 groups—finding an overall differ-
ence in mortality between placebo and treatment provides no 
information regarding potential differences in timing. Thus, 
in addition, we prespecified a comparison of the distribution 
of observed all-cause mortality between the groups using the 
Cramer–von Mises statistic. In essence, this examines timing 
differences controlling for the fact that the azithromycin group 
experienced less mortality.
We then examined whether the time of death showed evidence 
of an annual cycle by testing whether or not the magnitude of 
the first trigonometric moment was nonzero, and whether the 
seasonality of deaths was different in the 2 groups by a test of 
equality of first trigonometric moments. Finally, we compared 
the times of treatments of individuals who (later) died using tests 
of equality of first and second trigonometric moments on an 
intent-to-treat basis (see Supplementary Data for details). In all 
cases, we conducted permutation tests by randomization unit (to 
account for clustering). All computations were performed in the 
R statistical programming language, version 3.5 for MacIntosh 
(R Foundation for Statistical Computing, R package survival).
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RESULTS
Children in communities randomized to azithromycin had a 
lower mortality hazard than those in placebo-treated communi-
ties. The log-rank test revealed evidence of a difference between 
the intervention and control groups (P =  .004). Stratifying by 
country, we found a relative hazard of 0.81 (95% confidence 
interval [CI], .75–.87) for Niger, 0.96 (95% CI, .84–1.14) for 
Malawi, and 0.996 (95% CI, .80–1.24) for Tanzania (Cox pro-
portional hazard model). Kaplan-Meier curves for each country 
are given in Supplementary Figure 1. This analysis is similar to 
the primary analysis reported elsewhere [10].
It is possible that the timing of mortality among those who 
died may differ. Accordingly, for children who died, we com-
pared the probability distribution of the time elapsed between 
mortality and drug administration between the placebo and 
azithromycin groups. The Cramer–von Mises test revealed 
evidence of a difference in the distribution of the time from 
drug distribution to death (P = .01). Overall in the 3 countries, 
among children who died, they were less likely to have died 
early in the treatment arm relative to the control arm (Figure 1). 
The black curve shows the difference in distribution of mor-
tality times given that death occurred, adjusting for the fact that 
fewer deaths occurred in the treatment arm (note, in particular, 
that mortality in the treatment arm is lower than in the placebo 
arm, as shown by the Kaplan-Meier plots in the Supplementary 
Data). In addition, the difference in distribution of mortality 
times in each country is given in color, weighted by their rela-
tive contribution to the overall difference distribution.
We examined whether or not mortality reports occurred 
seasonally (Supplementary Figure  2). Specifically, we found 
evidence that the trigonometric mean occurrence time differed 
from zero, providing evidence of annual variation in mortality 
in Niger and Malawi (P < .001 and P < .001, respectively), but 
we did not find such evidence in Tanzania (P =  .33). We next 
compared differences in seasonality between the 2 arms in each 
country on an annual scale (test of equality of first trigonometric 
moments) and on a twice-yearly scale (test of equality of second 
trigonometric moments) (see Supplementary Data for details). 
We found no evidence of a difference in the overall annual sea-
sonal timing of deaths between the 2 arms on the annual scale 
in any country (P = .84, P = .78, and P = .33 for Niger, Malawi, 
and Tanzania, respectively). However, examination of the sec-
ond trigonometric moment (corresponding to a twice-yearly 
frequency) suggests a change in seasonality (P = .02, P < .001, 
and P = .59 for Niger, Malawi, and Tanzania, respectively). The 
Supplementary Figures provide further information.
Similarly, treatments in all countries were not evenly dis-
tributed throughout the year: P < .001, P < .001, and P < .001 
for Niger, Malawi, and Tanzania, respectively (Supplementary 
Figure 3). For those who died in the placebo arm, we found evi-
dence that the treatments had been offered seasonally in Niger 
and Malawi (P <  .001 and P <  .001, respectively, test that the 
trigonometric mean equals zero), but not in Tanzania (P = .17). 
Finally, we compared the timing of placebo and azithromycin 
treatments for those who died (using the trigonometric mean). 
We found no evidence of a difference on the annual scale when 
comparing treatment times of those who died (P = .91, P = .84, 
and P = .93 for Niger, Malawi, and Tanzania, respectively).
DISCUSSION
In the MORDOR trial, the hazard for death in children aged 
1–59  months in the time after distribution was significantly 
lower in communities randomized to azithromycin compared 
to placebo. This confirmation of the trial results is not surpris-
ing as the analysis was similar in principle to the primary out-
come where mortality was reduced 14%, estimated by negative 
binomial regression. However, we found that the distribution of 
the time from drug distribution to death differed significantly 
between the 2 arms. Note that this result, conditioned on a child 
having died, was not similar to the primary outcome. A general 
decrease in death could easily have resulted in a significant pri-
mary outcome, but not a different distribution contingent on 
death. That the largest effect was seen soon after the distribution 
is further evidence for an effect of oral azithromycin distribu-
tions. The deficit in deaths occurred in the first 3 months post–
antibiotic distribution. This suggests that further protection 
Figure 1. Excess mortality in the first 2 months in the control group, compared 
to the treatment group, is seen in the difference between estimated mortality time 
density estimates. The horizontal axis depicts time in days from the beginning of 
each phase. The vertical axis shows the difference between the density of mortality 
times in the control and treatment groups (smoothed with a Gaussian kernel of 
bandwidth 0.1 month). Results from Malawi are presented in red, Niger in purple, 
Tanzania in green, and total in black. Note that this displays the difference between 
2 probability distributions, and thus an excess at one time would necessarily be 
balanced by a deficit at another.
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might be achieved if distributions were given more frequently 
than biannually. If considered feasible, this would need to be 
evaluated in further trials.
The primary outcome of MORDOR was all-cause mortality, 
and analyses have so far not proven how exactly azithromycin 
had its effect [10]. Although the drug has modest anti-inflamma-
tory properties, the high-dose protocol we followed is expected 
to yield a therapeutic antimicrobial concentration for approxi-
mately 1 week [11]. Experts thought that the most likely mech-
anism would be an effect on respiratory infection, diarrhea, 
or malaria [12]. If the major effect were against Plasmodium 
falciparum, we might expect treatments given near the mal-
aria season (August–September) [13] to have a great effect on 
mortality. Evidence has suggested that childhood mortality risk 
in the Sahel (including Niger) is greatest when food supplies 
are scarce (the “lean season,” approximately May–September) 
[14] and during the malaria season [15], but we were unable to 
demonstrate that the season of death was different between the 
azithromycin- and placebo-treated communities. Similarly, we 
were unable to demonstrate that the season of treatment was an 
effect modifier, suggesting that any potential programs may not 
gain by timing distributions.
This secondary analysis has several limitations. For logistical 
reasons, the biannual MORDOR distributions were spread over 
6-month time periods. Study teams were instructed to treat 
subdistricts in the same approximate order each period, with 
a gap from the previous treatment of between 4 and 8 months 
[10]. The flexibility in distribution time was thus logistical, not 
random, and perhaps not the most efficient for assessing the 
optimal timing of treatment. The large simple trial design pre-
cluded intensive data collection on individual children. As mor-
tality was a relatively rare event, the power to assess whether 
timing of treatment was an effect modifier was low [16].
The previous MORDOR primary outcome proved that oral 
azithromycin distributions decrease all-cause mortality in post-
neonatal children in 3 sites in sub-Saharan Africa [10]. The 
distributions in the study were spread throughout the year, al-
lowing assessment of any seasonal effects. Here, we were un-
able to demonstrate that the season of distribution was an effect 
modifier, so we cannot recommend specific timing for treat-
ments. We were able to demonstrate that the greatest protection 
was found in the first 3 months postdistribution. Where feas-
ible, quarterly distributions could be assessed.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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